Anixa Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Anixa Biosciences has a total shareholder equity of $20.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $22.9M and $2.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$20.75m |
| Equity | US$20.69m |
| Total liabilities | US$2.22m |
| Total assets | US$22.91m |
Recent financial health updates
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate
Sep 12
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
May 23We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Recent updates
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate
Sep 12We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
May 23We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13
Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01Financial Position Analysis
Short Term Liabilities: ANIX's short term assets ($22.7M) exceed its short term liabilities ($2.0M).
Long Term Liabilities: ANIX's short term assets ($22.7M) exceed its long term liabilities ($213.0K).
Debt to Equity History and Analysis
Debt Level: ANIX is debt free.
Reducing Debt: ANIX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANIX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ANIX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 7.8% each year.